Short Interest in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Declines By 38.4%

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the recipient of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 51,582 shares, a drop of 38.4% from the June 30th total of 83,765 shares. Based on an average daily trading volume, of 36,650 shares, the days-to-cover ratio is presently 1.4 days. Currently, 5.2% of the company’s shares are sold short.

Virtus LifeSci Biotech Clinical Trials ETF Trading Down 3.0%

BBC stock traded down $1.53 during trading on Friday, hitting $48.74. 14,729 shares of the company traded hands, compared to its average volume of 24,062. Virtus LifeSci Biotech Clinical Trials ETF has a 1 year low of $20.87 and a 1 year high of $54.95. The company has a 50-day moving average of $47.69 and a 200-day moving average of $44.27.

Institutional Trading of Virtus LifeSci Biotech Clinical Trials ETF

An institutional investor recently bought a new stake in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC bought a new position in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned about 0.41% of Virtus LifeSci Biotech Clinical Trials ETF as of its most recent filing with the Securities & Exchange Commission.

About Virtus LifeSci Biotech Clinical Trials ETF

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.